Prime Medicine, Inc. Defined Contribution Plan, Cost
Prime Medicine, Inc. (PRME) reported Defined Contribution Plan, Cost of $100.00 thousand for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2022-11-14
- Prime Medicine, Inc. defined contribution plan, cost for the quarter ending 2022-09-30 was $100.00K.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 9 month |
|---|---|---|
| 2022-09-30 | $100.00K 10-Q · filed 2022-11-14 | $100.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |